AGP Executive Report
Last update: 7 hours agoDrug Pricing: India has capped trade margins on non-scheduled cancer medicines at 30% of retail price, a move expected to cut some prices by up to 70%. The Supreme Court also told the government to form a panel on pharmaceutical freebies to doctors and unethical marketing. Prescribing Practices: A Cochrane review of more than 93 studies found that industry payments, gifts and sales visits are linked to doctors prescribing promoted drugs more often, including potentially inappropriate treatments. New Treatments: The FDA granted fast track status to VIR-5500, an experimental therapy for advanced prostate cancer. A trial of a daily GLP-1 pill for type 2 diabetes reported HbA1c reductions of up to 1.6%. Care and Coverage: Doctors and radiologists are pushing back against a proposed change to the No Surprises Act, warning that replacing independent payment arbitration with median in-network rates could weaken safeguards against low insurer payments. Clinical Guidance: New UTI guidelines emphasize infection severity when choosing initial antibiotics, while noting that local resistance data may not reflect risk for every patient.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
